Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kataoka, Yu
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
GOAL-ASIA, NCT05325034: Guideline Oriented Approach to Lipid Lowering in Asia-Pacific	Recruiting	N/A	2000	Japan, RoW	Early Intervention	Stephen Nicholls, Amgen	Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia	12/24	12/24
Kasim, Sazzli
GOAL-ASIA, NCT05325034: Guideline Oriented Approach to Lipid Lowering in Asia-Pacific	Recruiting	N/A	2000	Japan, RoW	Early Intervention	Stephen Nicholls, Amgen	Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia	12/24	12/24